الفهرس | Only 14 pages are availabe for public view |
Abstract RVO is the second mostcommon retinal vascular disease after diabetic retinopathy.There are two types of retinal vein occlusion (RVO): central retinal veinocclusion (CRVO) and branch RVO (BRVO).Both CRVO and BRVO can be broadly classified into ischaemic and non-ischaemic types based on the area of capillary non-perfusion, and this distinction is useful for clinical management. Central retinal vein occlusion (CRVO) results from thrombosis of the central retinal vein when it passes through the lamina cribrosa. Branch retinal vein occlusion (BRVO) is caused by venous thrombosis at an arteriovenous crossing. Hypertension is a major risk factor for RVO. Other associated risk factors include hyperlipidemia, smoking, history of cardiovascular disease, Hyperhomocysteinaemia, Blood coagulation disorders and glaucoma. Thrombosis of the retinal veins causes an increase in retinal capillary pressure resulting in increased capillary permeability and leakage of fluid and blood into the retina . Co-existent retinal ischaemia may exacerbate this process by the production of vascular endothelial growth factor (VEGF) which in turn promotes retinal capillary permeability resulting in further development of ME, and promote new vessel formation principally but not exclusively involving the iris and angle in CRVO and the retina in BRVO. These complications can lead to neovascular glaucoma, vitreous haemorrhage and tractional retinal detachment with severe visual impairment. Patient usually suffers from visual loss whether gradual or sudden, photophobia and may progress to blind painful eye especially with ischemic forms of central retinal vein occlusion . Full ophthalmic examination should be carried out. Fundus examination show disc oedema, increased dilatation and tortuosity of all retinal veins , widespread deep and superficial haemorrhages, cotton wool spots, retinal oedema and capillary non-perfusion in all four quadrants of the retina. Optical coherence tomography is noninvasive investigation for detecting macular edema even in the presence of hemorrhages, Fundus fluorescein angiography which is done as soon as the hemorrhages have cleared if the patient’s vision is still depressed.Also some laboratory tests can be done to determine the etiology as PT, aPTT, serum protein electrophoresis and others. The management of RVO involves a multidisciplinary approachbetween the general physician and the ophthalmologist . The role of thegeneral physician is to manage any systemic risk factors with the aimof reducing the risk of the patient developing a further RVO or any nonoculartarget organ damage. Intravitreal injection ofAnti- VEGFs as bevacizumab, ranibizumab and Aflibercept is recommended for ME associated withboth branch and central retinal vein occlusions withreduction of CFT and improvement of VA, but the effects wear off and reinjections are usually necessary to maintain improvements . Corticosteroids can be used in RVO to reduce macular edema, thereby, improves the visual acuity. The drugs used either Intravitreal injection of triamcinolone acetonide ordexamethasone intravitrealimplant. Wereassociated with cataract progression andincreased IOP. Grid laser photocoagulation is recommended for treatmentof macular edema resulting from branchretinal -vein occlusionafter 3–4 monthly injections of anti-VEGFand scatter laser photocoagulationis used treatmentof neovascularization. Several other potential surgical treatment including pars plana vitrectomy, radial optic neurotomy, and laserinducedchorioretinal anastomosis which may improve visual acuity in patient with non-perfused CRVO but may be associated with significant ocular complication. |